Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability [abstract 686] - Baselga,J.; Herbst,R.; LoRusso,P. (Proc Am Soc Clin Oncol, 2000)